½ÃÀ庸°í¼­
»óǰÄÚµå
1305924

½ÅÀå ±â´É °Ë»ç ½ÃÀå : Á¦Ç° À¯Çüº°, °Ë»ç À¯Çüº°, ÃÖÁ¾ ¿ëµµº°(2023-2032³â)

Kidney Function Tests Market - By Product Type (Dipsticks, Reagents, Disposables), By Test Type (Urine Tests, Blood Tests), By End-use (Hospitals, Diagnostic Laboratories), 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 210 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ½ÅÀå ±â´É °Ë»ç ½ÃÀå ±Ô¸ð 2032³â±îÁö ´ëÆø È®´ëµÉ °ÍÀÔ´Ï´Ù. ³ë·É Àα¸°¡ Áõ°¡Çϸ鼭 ½ÅÀå Áúȯ¿¡ °É¸®±â ½¬¿öÁö¸ç ½ÅÀå ±â´É °Ë»çÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

WHO¿¡ µû¸£¸é Áß±¹¿¡¼­´Â 2020³â±îÁö 60¼¼ ÀÌ»ó Àα¸°¡ 4¾ï 200¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ½ÅÀå Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¾÷°è¿¡ ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, 2022³â 8¿ù ¹Ì±¹ º¸°Çº¹ÁöºÎ´Â ÀÇ·á Àη °­È­¸¦ À§ÇØ ¾à 6,000¸¸ ´Þ·¯¸¦ ÅõÀÚÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù.

Àüü ½ÅÀå ±â´É °Ë»ç ½ÃÀåÀº Á¦Ç°, °Ë»ç, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªÀ» ±âÁØÀ¸·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç°º°·Î´Â ÀÏȸ¿ë(disposable) ºÐ¾ß°¡ 2032³â±îÁö Å« ÆøÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÏȸ¿ëÀÇ ³ôÀº Á¤¹Ðµµ¿Í Á¤È®µµ´Â Å©·¹¾ÆÆ¼´Ñ, Ç÷Áß ¿ä¼ÒÁú¼Ò(BUN), ÀüÇØÁú ¼öÁØ µî ´Ù¾çÇÑ ÆÄ¶ó¹ÌÅÍÀÇ ÃøÁ¤ °­È­°¡ °¡´ÉÇϱ⠶§¹®¿¡ ÀÏȸ¿ëÀÇ Ã¤ÅÃÀ» ÁöÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÏȸ¿ëÀÇ Æí¸®ÇÔÀº °Ë»ç °úÁ¤À» °£¼ÒÈ­ÇÏ°í ½Ã°£À» Àý¾àÇϸç ÀÓ»ó ÇöÀåÀÇ ¿öÅ©Ç÷οì È¿À²¼ºÀ» ³ôÀÔ´Ï´Ù. ÀÏȸ¿ë °Ë»ç´Â Àü¹® °Ë»ç Àåºñ, ½Ã¾à, ¼÷·ÃµÈ ÀηÂÀ» ÇÊ¿ä·Î ÇÏÁö ¾Ê±â ¶§¹®¿¡ Àüü °Ë»ç ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°Ë»ç¿¡ µû¸£¸é Ç÷¾× °Ë»ç ºÐ¾ßÀÇ »ê¾÷ °¡Ä¡´Â 2032³â±îÁö Å« ÆøÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ÅÀå ±â´É Àå¾ÖÀÇ Á¶±â ¹ß°ß ¹× Áø´Ü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Ç÷¾× °Ë»çÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¸¼º ½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÌ·¯ÇÑ ÁúȯÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Á¤±âÀûÀÎ Ç÷¾× °Ë»ç´Â Áúº´ÀÇ ÁøÇàÀ» ÃßÀûÇϰí, Ä¡·á È¿°ú¸¦ Æò°¡Çϰí, °ü¸® °áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó º´¿ø ºÎ¹®ÀÇ ¾÷°è Á¡À¯À²Àº 2023-2032³â »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀÔ´Ï´Ù. ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½Å¼ÓÇÑ ½ÅÀå ±â´É °Ë»ç¸¦ À§ÇØ º´¿øÀ» ã´Â ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼³µéÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ ÃֽŠÁø´Ü Àåºñ¸¦ ±¸ºñÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´¿ø ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¤ºÎÀÇ ÅõÀÚ°¡ ±ÞÁõÇϸ鼭 ÀÌ ºÐ¾ßÀÇ ¼ºÀå ±âȸ°¡ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÅÀå ±â´É °Ë»ç ½ÃÀå Á¡À¯À²Àº 2023-2032³â »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀÔ´Ï´Ù. ½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ÀÌ Áö¿ª¿¡¼­ ½ÅÀå ±â´É °Ë»çÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. IBEF¿¡ µû¸£¸é 2023-24³â ¿¬¹æ ¿¹»ê¿¡¼­ Á¤ºÎ´Â º¸°Ç °¡Á· º¹ÁöºÎ¿¡ 107¾ï 6,000¸¸ ´Þ·¯¸¦ Áö¿øÇßÀ¸¸ç, ºü¸£°Ô È®ÀåµÇ´Â ÀÇ·á ÀÎÇÁ¶ó´Â Áö¿ª È®Àå¿¡ ´ëÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

  • »ê¾÷ Ä¿¹ö¸®Áö
  • ½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
  • ±âº» ÃßÁ¤°ú ÀÛ¾÷
    • µ¥ÀÌÅÍ ¼öÁý
  • ¿¹Ãø ÆÄ¶ó¹ÌÅÍ
  • ¼¼°è ·¹º§¿¡¼­ÀÇ COVID-19ÀÇ ¿µÇâ
  • µ¥ÀÌÅÍ °ËÁõ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ µ¥ÀÌÅÍ
    • 2Â÷
      • À¯·á Á¤º¸¿ø
      • ¹«º¸¼ö Á¤º¸¿ø

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÅÀå ±â´É °Ë»ç ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸¸¼º½ÅÀ庴 ¹× ±Þ¼º ½Å¼Õ»óÀÇ À¯º´·ü »ó½Â
      • ½ÅÀå °ü·Ã Áúȯ¿¡ ´ëÇÑ ´Ù¾çÇÑ Áø´Ü ¹æ¹ýÀÇ ÀÌ¿ë °¡´É¼º¿¡ °üÇÑ ÀǽÄÀÇ Çâ»ó
      • ´ç´¢º´ ¹× °íÇ÷¾Ð ȯÀÚÀÇ Áõ°¡
      • ´Ù¾çÇÑ ½ÅÀå ±â´É °Ë»ç¿¡ ´ëÇÑ ¿¬±¸°³¹ß ÅõÀÚÀÇ Áõ°¡¿Í ÇÔ²² ±â¼úÀÇ Áøº¸
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ½ÅÀ庴¿¡ °üÇÑ ÀÎ½Ä ºÎÁ·
  • ¼ºÀå °¡´É¼º ºÐ¼®
    • Á¦Ç° À¯Çüº°
    • °Ë»ç À¯Çüº°
    • ÃÖÁ¾ ¿ëµµº°
  • COVID-19 ¿µÇ⠺м®
  • »óȯ ½Ã³ª¸®¿À
    • ¹Ì±¹
  • ±â¼ú Àü¸Á
  • ¸¸¼º½ÅÀ庴(CKD) È÷Æ®¸Ê
  • »ç±¸Ã¼ ¿©°ú·® °Ë»çÀÇ °³¿ä
  • ½ÅÀå ±â´É °Ë»ç °³³ä °³¿ä
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ, 2022³â

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®, 2022³â
  • °æÀï Æ÷Áö¼Å´×¡¤¸ÅÆ®¸¯½º
  • º¥´õ¡¤¸ÅÆ®¸¯½º ºÐ¼®
  • Àü·« ´ë½Ãº¸µå, 2022³â

Á¦5Àå ½ÅÀå ±â´É °Ë»ç ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç° À¯Çüº°

  • ÁÖ¿ä µ¿Çâ : Á¦Ç° À¯Çüº°
  • µö½ºÆ½
  • ½Ã¾à
  • ÀÏȸ¿ë

Á¦6Àå ½ÅÀå ±â´É °Ë»ç ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : °Ë»ç À¯Çüº°

  • ÁÖ¿ä µ¿Çâ : °Ë»ç À¯Çüº°
  • ¿ä°Ë»ç
    • ´¢ ´Ü¹éÁú °Ë»ç
    • ¸¶ÀÌÅ©·Î ¾ËºÎ¹Î °Ë»ç
    • Å©·¹¾ÆÆ¼´Ñ Ŭ¸®¾î·±½º °Ë»ç
  • Ç÷¾×°Ë»ç
    • Ç÷û Å©·¹¾ÆÆ¼´Ñ °Ë»ç
    • Ç÷Áß ¿ä¼Ò Áú¼Ò °Ë»ç
    • »ç±¸Ã¼ ¿©°úÀ² °Ë»ç

Á¦7Àå ½ÅÀå ±â´É °Ë»ç ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾ ¿ëµµº°
  • º´¿ø
  • Áø´Ü ¿¬±¸¼Ò
  • ±âŸ

Á¦8Àå ½ÅÀå ±â´É °Ë»ç ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • Æú¶õµå
    • ½º¿þµ§
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
    • Çʸ®ÇÉ
    • º£Æ®³²
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • Ä¥·¹
    • Æä·ç
  • MEA
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ÅÍŰ
    • À̽º¶ó¿¤
    • À̶õ

Á¦9Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH
  • Quest Diagnostics
  • Nova Biomedical
  • 77 Elektronika Kft
  • ACON Laboratories, Inc.
  • Sekisui Diagnostics
  • Akers Biosciences, Inc.
  • URIT Medical
  • ARKRAY
  • Baxter International Inc.
  • PRIMA Lab SA
  • Eurofins Scientific
  • Bio-Rad Laboratories, Inc.
  • Idexx Laboratories
  • VedaLab
KSA 23.07.28

Global Kidney Function Tests Market size will expand substantially through 2032. Growing geriatric population's susceptibility to kidney disorders has increased the need for kidney function tests. As per WHO, in China, the population of people aged 60 years and over will reach 402 million by 2040. Moreover, flourishing healthcare infrastructure coupled with growing awareness about kidney disorders is presenting growth opportunities to the industry. In August 2022, the U.S. Department of Health and Human Services announced an investment of around USD 60 million to strengthen the healthcare workforce.

The overall kidney function tests market is categorized based on product, test, end-use, and region.

Based on the product, industry value from the disposables segment will register huge significant gains through 2032. High accuracy and precision of disposables allow for enhanced measurement of various parameters, such as creatinine, blood urea nitrogen (BUN), and electrolyte levels, favoring their adoption. Additionally, the simplicity of disposables streamlines the testing process, saves time, and enhances workflow efficiency in clinical settings. They eliminate the need for specialized laboratory equipment, reagents, and skilled personnel, reducing overall testing costs.

Based on the test, industry value from the blood tests segment will register huge gains through 2032. Growing awareness about the early detection and diagnosis of kidney dysfunction has increased the need for blood tests. Moreover, the rising prevalence of chronic kidney disease has further propelled the demand for such tests for the early detection of the condition. Regular blood tests help track disease progression, assess treatment efficacy, and guide management decisions.

Based on the end-use, industry share from the hospitals segment will grow at a notable CAGR from 2023 to 2032. High availability of skilled healthcare professionals has increased patient footfall in hospitals for rapid kidney function tests. These facilities are increasingly getting equipped with modern diagnostic devices for enhanced patient outcomes. Moreover, surging investments by the government in hospital infrastructure is further creating a plethora of opportunities for segment growth.

From the regional perspective, the Asia Pacific kidney function tests market share will grow at a notable CAGR from 2023 to 2032. Rising prevalence of kidney disorders has increased the need for kidney function tests in the region. Moreover, rapidly expanding healthcare infrastructure is presenting growth opportunities for regional expansion. As per IBEF, in the Union Budget 2023-24, the government awarded USD 10.76 billion to the Ministry of Health and Family Welfare.

Table of Contents

Chapter 1 Methodology

  • 1.1 Industry coverage
  • 1.2 Market scope & definitions
  • 1.3 Base estimates & working
    • 1.3.1 Data collection
  • 1.4 Forecast parameters
  • 1.5 COVID-19 impact at global level
  • 1.6 Data validation
  • 1.7 Data sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Kidney function tests industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Product type trends
    • 2.1.4 Test type trends
    • 2.1.5 End-use trends

Chapter 3 Kidney Function Tests Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic kidney diseases and acute kidney injuries
      • 3.2.1.2 Surging awareness regarding availability of different diagnostic methods for kidney related disorders
      • 3.2.1.3 Increasing patient population for diabetes and hypertension
      • 3.2.1.4 Technological advancements coupled with rise in R&D investments for different kidney function tests.
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of awareness regarding kidney diseases
  • 3.3 Growth potential analysis
    • 3.3.1 By product type
    • 3.3.2 By test type
    • 3.3.3 By end-use
  • 3.4 COVID-19 impact analysis
  • 3.5 Reimbursement scenario
    • 3.5.1 U.S.
  • 3.6 Technology landscape
  • 3.7 Chronic Kidney Disease (CKD) Heat Map
  • 3.8 Glomerular filtration rate tests outline
  • 3.9 Kidney function tests conceptual overview
  • 3.10 Future market trends
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive positioning matrix
  • 4.4 Vendor matrix analysis
  • 4.5 Strategy dashboard, 2022

Chapter 5 Kidney Function Tests Market Size and Forecast, By Product Type (USD Million & Units)

  • 5.1 Key product type trends
  • 5.2 Dipsticks
  • 5.3 Reagents
  • 5.4 Disposables

Chapter 6 Kidney Function Tests Market Size and Forecast, By Test Type (USD Million)

  • 6.1 Key test type trends
  • 6.2 Urine tests
    • 6.2.1 Urine Protein Tests
    • 6.2.2 Microalbumin Tests
    • 6.2.3 Creatinine Clearance Tests
  • 6.3 Blood Tests
    • 6.3.1 Serum Creatinine Tests
    • 6.3.2 Blood Urea Nitrogen Tests
    • 6.3.3 Glomerular Filtration Rate Tests

Chapter 7 Kidney Function Tests Market Size and Forecast, By End-use (USD Million)

  • 7.1 Key end-use trends
  • 7.2 Hospitals
  • 7.3 Diagnostic Laboratories
  • 7.4 Others

Chapter 8 Kidney Function Tests Market Size and Forecast, By Region (USD Million & Units)

  • 8.1 Key regional trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Poland
    • 8.3.7 Sweden
    • 8.3.8 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Indonesia
    • 8.4.7 Philippines
    • 8.4.8 Vietnam
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Columbia
    • 8.5.5 Chile
    • 8.5.6 Peru
  • 8.6 MEA
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Turkey
    • 8.6.5 Israel
    • 8.6.6 Iran

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Danaher Corporation
  • 9.3 F. Hoffmann-La Roche Ltd.
  • 9.4 Siemens Healthcare GmbH
  • 9.5 Quest Diagnostics
  • 9.6 Nova Biomedical
  • 9.7 77 Elektronika Kft
  • 9.8 ACON Laboratories, Inc.
  • 9.9 Sekisui Diagnostics
  • 9.10 Akers Biosciences, Inc.
  • 9.11 URIT Medical
  • 9.12 ARKRAY
  • 9.13 Baxter International Inc.
  • 9.14 PRIMA Lab SA
  • 9.15 Eurofins Scientific
  • 9.16 Bio-Rad Laboratories, Inc.
  • 9.17 Idexx Laboratories
  • 9.18 VedaLab
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦